February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

In recent weeks, global markets have been grappling with geopolitical tensions and concerns over consumer spending, leading to fluctuations in major indices such as the S&P 500 and Dow Jones ...

Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a ...

Celltrion's autoimmune disease treatment, Remsima, has surpassed 1.2 trillion won ($837 million) in annual sales, making it ...

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, has emerged as the most-prescribed medicine in Europe. According ...

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion, a major Korean biopharmaceutical firm, said Tuesday its fourth quarter net profit had skyrocketed from a year ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Tuesday its fourth-quarter net profit skyrocketed from a year earlier on robust sales of biosimilar medicines and the merger with its ...

SEOUL, Feb. 25 (Yonhap) -- Celltrion on Tuesday reported its 2024 net profit of 418.9 billion won (US$292.8 million), down 22.4 percent from a year earlier. The company said in a regulatory filing ...